公开(公告)号：US11998617B2

公开(公告)日：2024-06-04

申请号：US17358774

申请日：2021-06-25

Applicant: CURAMYS INC.

Inventor： Jung-Joon Sung ,  Seung-Yong Seong ,  Hee-Woo Lee ,  Ki Yoon Kim

IPC: A61K48/00 ,  A61K35/30 ,  A61K35/545 ,  A61P21/00 ,  A61P25/00 ,  C07K14/005 ,  C12N5/0735 ,  C12N5/074 ,  C12N5/0775 ,  C12N5/0793 ,  C12N5/12 ,  C12N5/16 ,  C12N9/24 ,  C12N15/85 ,  A61K38/00

CPC classification number: A61K48/005 ,  A61K35/30 ,  A61K35/545 ,  A61P21/00 ,  A61P25/00 ,  C07K14/005 ,  C12N5/0606 ,  C12N5/0619 ,  C12N5/0667 ,  C12N5/0696 ,  C12N5/12 ,  C12N5/16 ,  C12N9/2402 ,  C12N15/85 ,  A61K38/00 ,  C12N2760/18822 ,  C12N2760/18833

Abstract: The present invention relates to gene and cell therapy using a cell fusion technology and more particularly, cells overexpressing hemagglutinin neuraminidase (HN) and fusion (F) proteins have effects of enhancing cell fusion with other cells, restoring cell damage through the cell fusion with damaged cells, and transferring a normal gene. Therefore, when a vector including genes encoding the HN and F proteins of the present invention or a cell transformed with the vector is clinically applied to neurodegenerative diseases, muscular diseases, and the like, an effect of reducing the damage of damaged cells through cell fusion can be expected.

公开(公告)号：US20240124898A1

公开(公告)日：2024-04-18

申请号：US18467297

申请日：2023-09-14

Applicant: OSAKA UNIVERSITY

Inventor： Tomoji MASHIMO ,  Junji TAKEDA ,  Hiroyuki MORISAKA ,  Kazuto YOSHIMI

IPC: C12N15/90 ,  A61K48/00 ,  C12N5/14 ,  C12N5/16 ,  C12N9/22 ,  C12N15/85

CPC classification number: C12N15/907 ,  A61K48/00 ,  C12N5/14 ,  C12N5/16 ,  C12N9/22 ,  C12N15/85 ,  C12N15/8509 ,  C12N2310/20 ,  C12N2800/22 ,  C12N2800/80

Abstract: A CRISPR-Cas3 system was successfully established in a eukaryotic cell.

公开(公告)号：US20240123055A1

公开(公告)日：2024-04-18

申请号：US18380479

申请日：2023-10-16

Applicant: Longhorn Vaccines and Diagnostics, LLC

Inventor： Gerald W. Fischer ,  Clara J. Sei ,  Jeffrey D. Fischer

IPC: A61K39/215 ,  A61K39/015 ,  A61K39/04 ,  A61K39/085 ,  A61K39/145 ,  A61K39/21 ,  A61P31/04 ,  A61P31/12 ,  A61P31/16 ,  C07K14/005 ,  C07K16/08 ,  C07K16/12 ,  C07K16/20 ,  C08G69/10 ,  C12N5/16 ,  C12N7/00

CPC classification number: A61K39/215 ,  A61K39/015 ,  A61K39/04 ,  A61K39/085 ,  A61K39/145 ,  A61K39/21 ,  A61P31/04 ,  A61P31/12 ,  A61P31/16 ,  C07K14/005 ,  C07K16/08 ,  C07K16/12 ,  C07K16/205 ,  C08G69/10 ,  C12N5/16 ,  C12N7/00 ,  A61K2039/55544 ,  C12N2760/16022 ,  C12N2760/16034 ,  C12N2760/16071 ,  C12N2770/20022 ,  C12N2770/20034 ,  C12N2770/20071

Abstract: The invention relates to compositions and peptides or peptide sequences that induce an immune response in an animal or a mammal that is protective against infection by one or more pathogens. In addition, the invention relates to immunogenic composition and vaccines comprising compositions and peptide sequences and to method for treating and preventing an infection in animals and mammals such as humans and antibodies.

公开(公告)号：US20240024474A1

公开(公告)日：2024-01-25

申请号：US18031260

申请日：2021-11-12

Applicant: David Avigan ,  Jacalyn Rosenblatt ,  Donald Kufe ,  Dana-Farber Cancer Institute, Inc. ,  Beth Istael Deaconess Medical Center

Inventor： David Avigan ,  Jacalyn Rosenblatt ,  Donald Kufe

IPC: A61K39/00 ,  A61K39/395 ,  A61K38/19 ,  A61K38/17 ,  A61K47/36 ,  A61P35/00 ,  A61P35/02 ,  C12N5/0783 ,  C12N5/16

CPC classification number: A61K39/4611 ,  A61K39/3955 ,  A61K39/4631 ,  A61K39/464412 ,  A61K39/464417 ,  A61K38/191 ,  A61K38/1709 ,  A61K47/36 ,  A61P35/00 ,  A61P35/02 ,  C12N5/0636 ,  C12N5/16 ,  A61K2039/5158 ,  C12N2502/99 ,  C12N2533/74 ,  C12N2501/998

Abstract: The present invention provides compositions and methods for treating cancer.

公开(公告)号：US11865189B2

公开(公告)日：2024-01-09

申请号：US15536725

申请日：2015-12-17

Applicant: SORBONNE UNIVERSITE ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

Inventor： Thierry Leveillard ,  Christo Kole ,  Jose-Alain Sahel

IPC: A61K48/00 ,  C12N5/079 ,  C12N15/864 ,  A61K35/12 ,  C12N7/00 ,  C12N5/16

CPC classification number: A61K48/0058 ,  A61K35/12 ,  A61K48/00 ,  C12N5/0621 ,  C12N5/16 ,  C12N7/00 ,  C12N15/8645 ,  C12N2510/00 ,  C12N2750/14141

Abstract: The present invention relates to methods and composition for use in the treatment of retinal degeneration, in particular retinal degeneration due to retinal pigment epithelium dysfunction.

公开(公告)号：US11857574B2

公开(公告)日：2024-01-02

申请号：US18054521

申请日：2022-11-10

Applicant: CRISPR Therapeutics AG

Inventor： Mary-Lee Dequeant ,  Demetrios Kalaitzidis ,  Mohammed Ghonime

IPC: A61K35/17 ,  C07K14/705 ,  C12N5/0783 ,  C12N9/22 ,  C12N15/01 ,  C07K14/725 ,  C07K16/28 ,  C12N5/16 ,  C12N15/113 ,  C12N15/86 ,  A61K38/00 ,  C12N15/11

CPC classification number: A61K35/17 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/70575 ,  C07K14/70578 ,  C07K14/70596 ,  C07K16/2803 ,  C07K16/2875 ,  C07K16/2878 ,  C12N5/0636 ,  C12N5/16 ,  C12N9/22 ,  C12N15/111 ,  C12N15/113 ,  C12N15/86 ,  A61K38/00 ,  C07K2317/622 ,  C12N2310/20 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2510/00

Abstract: A population of genetically engineered T cells, comprising a disrupted Reg1 gene and/or a disrupted TGFBRII gene. Such genetically engineered T cells may comprise further genetic modifications, for example, a disrupted CD70 gene. The population of genetically engineered T cells exhibit one or more of (a) improved cell growth activity; (b) enhanced persistence; and (c) reduced T cell exhaustion, (d) enhanced cytotoxicity activity, (e) resistant to inhibitory effects induced by TGF-b, and (f) resistant to inhibitory effects by fibroblasts and/or inhibitory factors secreted thereby, as compared to non-engineered T cell counterparts.

公开(公告)号：US11779629B2

公开(公告)日：2023-10-10

申请号：US16999849

申请日：2020-08-21

Applicant: The University of British Columbia

Inventor： Neil R. Cashman

IPC: A61K38/00 ,  A61K38/17 ,  C07K7/00 ,  C07K5/12 ,  A61K38/07 ,  A61K38/12 ,  A61K39/385 ,  A61K47/64 ,  C07K14/47 ,  C07K5/117 ,  C07K7/06 ,  C07K7/64 ,  C12N5/16 ,  G01N33/68 ,  A61P25/28 ,  C07K16/18 ,  C07K5/083 ,  C07K5/087 ,  C07K5/09 ,  C07K5/093 ,  C07K5/097 ,  C07K5/113 ,  A61K39/00 ,  A61K51/08 ,  A61K49/18 ,  A61K45/00 ,  A61K39/395 ,  A61K38/05 ,  A61K51/10 ,  A61K47/68 ,  A61K38/08 ,  A61K39/39 ,  A61K45/06 ,  A61K47/69 ,  A61L31/10 ,  A61L27/34 ,  A61L29/16 ,  A61L31/16 ,  A61L29/08 ,  A61L27/22 ,  G01N33/50 ,  C07K5/103 ,  C07K14/435 ,  C12N5/10 ,  C07K7/08

CPC classification number: A61K38/07 ,  A61K38/12 ,  A61K39/385 ,  A61K47/643 ,  A61K47/646 ,  A61P25/28 ,  C07K5/081 ,  C07K5/0808 ,  C07K5/0812 ,  C07K5/0815 ,  C07K5/0819 ,  C07K5/0821 ,  C07K5/1021 ,  C07K5/1024 ,  C07K7/06 ,  C07K7/64 ,  C07K14/4711 ,  C07K16/18 ,  C12N5/16 ,  G01N33/6896 ,  A61K38/00 ,  A61K38/05 ,  A61K38/08 ,  A61K39/00 ,  A61K39/39 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/39533 ,  A61K45/05 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6921 ,  A61K49/1818 ,  A61K49/1866 ,  A61K51/088 ,  A61K51/10 ,  A61K51/1018 ,  A61K2039/505 ,  A61K2039/55505 ,  A61K2039/6081 ,  A61K2300/00 ,  A61L27/227 ,  A61L27/34 ,  A61L29/085 ,  A61L29/16 ,  A61L31/10 ,  A61L31/16 ,  C07K5/101 ,  C07K7/08 ,  C07K14/435 ,  C07K2317/20 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/624 ,  C07K2317/626 ,  C07K2317/70 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00 ,  C12N5/10 ,  G01N33/5058 ,  G01N2333/4709 ,  G01N2800/28 ,  G01N2800/2821 ,  G01N2800/387

Abstract: The disclosure pertains to methods of treating or preventing a disease or condition associated with and/or induced by soluble A-beta oligomer such as Alzheimer's disease by administering to a subject in need thereof conformation specific and/or selective antibodies or binding fragments thereof and related products.

公开(公告)号：US11773181B2

公开(公告)日：2023-10-03

申请号：US16990622

申请日：2020-08-11

Applicant: Health Research, Inc.

Inventor： Robert A. Fenstermaker ,  Michael J. Ciesielski

IPC: C07K16/28 ,  C07K16/30 ,  A61K39/395 ,  C07K16/18 ,  C12N15/113 ,  C12N15/62 ,  A61K35/17 ,  C12N5/16 ,  C12N5/0783 ,  A61K39/00

CPC classification number: C07K16/30 ,  C07K16/18 ,  A61K35/17 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/92 ,  C12N5/0636 ,  C12N5/16 ,  C12N15/1136 ,  C12N15/62 ,  C12N2510/00

Abstract: Provided are survivin specific antibodies, nucleic acids encoding the antibodies and methods for treating tumors comprising survivin-expressing cells by administration of the antibodies. The antibody compositions were found to be effective in inhibiting the growth of tumors.

公开(公告)号：US20230295319A1

公开(公告)日：2023-09-21

申请号：US18178819

申请日：2023-03-06

Applicant: University of Florida Research Foundation, Incorporated

Inventor： Scott A. Rivkees ,  Christopher Wendler ,  Lung-Ji Chang

IPC: C07K16/28 ,  C12N5/16 ,  A61K48/00 ,  C12N9/64 ,  C12N15/86 ,  A61P35/00 ,  A61K35/17 ,  C07K14/725 ,  C07K14/705

CPC classification number: C07K16/2869 ,  A61K35/17 ,  A61K48/005 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/70596 ,  C12N5/16 ,  C12N9/6472 ,  C12N15/86 ,  C12Y304/22062 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/70 ,  C12N2740/16043

Abstract: Aspects of the disclosure relate to chimeric antigen receptors (CARs) comprising an antigen binding domain (e.g., anti-TSHR), transmembrane domain (e.g., CD28), and a cytoplasmic domain (e.g., CD27, CD-137, etc.) and a safety mechanism comprising an inducible apoptosis trigger. In some aspects, the disclosure relates to use of the CARs in T cells, compositions, kits and methods for the treatment of thyroid cancers.

公开(公告)号：US11739159B2

公开(公告)日：2023-08-29

申请号：US17811904

申请日：2022-07-12

Applicant: PEPTRON, INC.

Inventor： Kyung Duk Moon ,  Ho Il Choi

IPC: C07K16/30 ,  C12N5/16 ,  A61K47/65 ,  A61K47/68 ,  C12N15/62 ,  G01N33/574

CPC classification number: C07K16/3092 ,  A61K47/65 ,  A61K47/6851 ,  C12N15/62 ,  G01N33/574 ,  C07K2317/34 ,  C12N5/16

Abstract: The present invention relates to an anti-MUC1 antibody binding specifically to Mucin 1 (MUC1) or an antigen-binding fragment thereof, an antibody-drug conjugate or bispecific antibody comprising the antibody, a pharmaceutical composition for prevention or treatment of cancer, comprising the same antibody, conjugate or bispecific antibody, and a nucleic acid encoding the same antibody, a vector and a host cell, both carrying the same nucleic acid, and a method for preparing an anti-MUC1 antibody or an antigen-binding fragment thereof, using the same vector and host cell. According to the present invention, the antibody shows outstanding affinity and binding force to MUC1 and the antibody-drug conjugate can bind specifically to a MUC1-expressing cell to specifically or selectively transfer the drug with efficacy. Therefore, the anti-MUC1 antibody and the antibody-drug conjugate according to the present invention can be usefully applied to the treatment of a MUC1-related disease, for example, cancer.